Shares of Oncternal Therapeutics ONCT rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 52.94% over the past year to ($0.16), which missed the estimate of ($0.14).
Revenue of $883,000 higher by 41.73% year over year, which missed the estimate of $1,090,000.
Guidance
Oncternal Therapeutics hasn't issued any earnings guidance for the time being.
Oncternal Therapeutics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 05, 2021
Time: 05:00 PM
ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/onct/mediaframe/44613/indexl.html
Price Action
Company's 52-week high was at $10.56
52-week low: $1.49
Price action over last quarter: down 30.04%
Company Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. Its product pipeline includes Cirmtuzumab, TK216, and ROR1 CAR-T.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.